Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer

Kazuhiro Kitajima, Koji Murakami, Erena Yamasaki, Shingo Hagiwara, Ichio Fukasawa, Noriyuki Inaba, Yasushi Kaji, Kazuro Sugimura

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Objective: To evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) using 18-F-fluorodeoxyglucose (FDG), compared with PET alone, in the diagnosis of suspected endometrial cancer recurrence. Methods: Thirty women who had undergone primary surgery for histopathologically proven endometrial cancer with suspected recurrence because of clinical, cytological, biochemical, and/or radiological findings were enrolled in this study. PET and integrated PET/CT images were evaluated by two different experienced radiologists by consensus for each modality. A final diagnosis of recurrence was confirmed by histopathology, other imaging and clinical follow-up for longer than 1 year. The statistical significance of differences between PET and PET/CT was determined by the McNemar test. Results: Patient-based analysis showed that the sensitivity, specificity, and accuracy of PET/CT were 93% (14/15), 93% (14/15), and 93% (28/30), respectively, whereas for PET, the corresponding data were 80% (12/15), 80% (12/15), and 80% (24/30), respectively (P = 0.479, 0.479, and 0.134, respectively). CT from PET/CT resolved the false-positive PET results because of hyper-metabolic activity of benign inflammatory lesions and physiological variants and moreover detected lung metastasis and para-aortic lymph node metastasis that PET missed. However, tiny para-aortic lymph node metastasis could not be detected even with PET/CT. Conclusions: Integrated FDG-PET/CT is a useful complementary modality for providing good anatomic and functional localization of sites of recurrence during follow-up of patients with endometrial cancer.

Original languageEnglish
Pages (from-to)103-109
Number of pages7
JournalAnnals of Nuclear Medicine
Volume22
Issue number2
DOIs
Publication statusPublished - 2008 Feb
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Recurrence
Neoplasm Metastasis
Lymph Nodes
Fluorodeoxyglucose F18
Positron Emission Tomography Computed Tomography
Sensitivity and Specificity
Lung

Keywords

  • F-FDG
  • Endometrial cancer
  • PET/CT
  • Recurrence

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Kitajima, K., Murakami, K., Yamasaki, E., Hagiwara, S., Fukasawa, I., Inaba, N., ... Sugimura, K. (2008). Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. Annals of Nuclear Medicine, 22(2), 103-109. https://doi.org/10.1007/s12149-007-0087-y

Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. / Kitajima, Kazuhiro; Murakami, Koji; Yamasaki, Erena; Hagiwara, Shingo; Fukasawa, Ichio; Inaba, Noriyuki; Kaji, Yasushi; Sugimura, Kazuro.

In: Annals of Nuclear Medicine, Vol. 22, No. 2, 02.2008, p. 103-109.

Research output: Contribution to journalArticle

Kitajima, K, Murakami, K, Yamasaki, E, Hagiwara, S, Fukasawa, I, Inaba, N, Kaji, Y & Sugimura, K 2008, 'Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer', Annals of Nuclear Medicine, vol. 22, no. 2, pp. 103-109. https://doi.org/10.1007/s12149-007-0087-y
Kitajima K, Murakami K, Yamasaki E, Hagiwara S, Fukasawa I, Inaba N et al. Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. Annals of Nuclear Medicine. 2008 Feb;22(2):103-109. https://doi.org/10.1007/s12149-007-0087-y
Kitajima, Kazuhiro ; Murakami, Koji ; Yamasaki, Erena ; Hagiwara, Shingo ; Fukasawa, Ichio ; Inaba, Noriyuki ; Kaji, Yasushi ; Sugimura, Kazuro. / Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer. In: Annals of Nuclear Medicine. 2008 ; Vol. 22, No. 2. pp. 103-109.
@article{226cb53fe3d942d496b796b3f3c1804e,
title = "Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer",
abstract = "Objective: To evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) using 18-F-fluorodeoxyglucose (FDG), compared with PET alone, in the diagnosis of suspected endometrial cancer recurrence. Methods: Thirty women who had undergone primary surgery for histopathologically proven endometrial cancer with suspected recurrence because of clinical, cytological, biochemical, and/or radiological findings were enrolled in this study. PET and integrated PET/CT images were evaluated by two different experienced radiologists by consensus for each modality. A final diagnosis of recurrence was confirmed by histopathology, other imaging and clinical follow-up for longer than 1 year. The statistical significance of differences between PET and PET/CT was determined by the McNemar test. Results: Patient-based analysis showed that the sensitivity, specificity, and accuracy of PET/CT were 93{\%} (14/15), 93{\%} (14/15), and 93{\%} (28/30), respectively, whereas for PET, the corresponding data were 80{\%} (12/15), 80{\%} (12/15), and 80{\%} (24/30), respectively (P = 0.479, 0.479, and 0.134, respectively). CT from PET/CT resolved the false-positive PET results because of hyper-metabolic activity of benign inflammatory lesions and physiological variants and moreover detected lung metastasis and para-aortic lymph node metastasis that PET missed. However, tiny para-aortic lymph node metastasis could not be detected even with PET/CT. Conclusions: Integrated FDG-PET/CT is a useful complementary modality for providing good anatomic and functional localization of sites of recurrence during follow-up of patients with endometrial cancer.",
keywords = "F-FDG, Endometrial cancer, PET/CT, Recurrence",
author = "Kazuhiro Kitajima and Koji Murakami and Erena Yamasaki and Shingo Hagiwara and Ichio Fukasawa and Noriyuki Inaba and Yasushi Kaji and Kazuro Sugimura",
year = "2008",
month = "2",
doi = "10.1007/s12149-007-0087-y",
language = "English",
volume = "22",
pages = "103--109",
journal = "Annals of Nuclear Medicine",
issn = "0914-7187",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Performance of FDG-PET/CT in the diagnosis of recurrent endometrial cancer

AU - Kitajima, Kazuhiro

AU - Murakami, Koji

AU - Yamasaki, Erena

AU - Hagiwara, Shingo

AU - Fukasawa, Ichio

AU - Inaba, Noriyuki

AU - Kaji, Yasushi

AU - Sugimura, Kazuro

PY - 2008/2

Y1 - 2008/2

N2 - Objective: To evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) using 18-F-fluorodeoxyglucose (FDG), compared with PET alone, in the diagnosis of suspected endometrial cancer recurrence. Methods: Thirty women who had undergone primary surgery for histopathologically proven endometrial cancer with suspected recurrence because of clinical, cytological, biochemical, and/or radiological findings were enrolled in this study. PET and integrated PET/CT images were evaluated by two different experienced radiologists by consensus for each modality. A final diagnosis of recurrence was confirmed by histopathology, other imaging and clinical follow-up for longer than 1 year. The statistical significance of differences between PET and PET/CT was determined by the McNemar test. Results: Patient-based analysis showed that the sensitivity, specificity, and accuracy of PET/CT were 93% (14/15), 93% (14/15), and 93% (28/30), respectively, whereas for PET, the corresponding data were 80% (12/15), 80% (12/15), and 80% (24/30), respectively (P = 0.479, 0.479, and 0.134, respectively). CT from PET/CT resolved the false-positive PET results because of hyper-metabolic activity of benign inflammatory lesions and physiological variants and moreover detected lung metastasis and para-aortic lymph node metastasis that PET missed. However, tiny para-aortic lymph node metastasis could not be detected even with PET/CT. Conclusions: Integrated FDG-PET/CT is a useful complementary modality for providing good anatomic and functional localization of sites of recurrence during follow-up of patients with endometrial cancer.

AB - Objective: To evaluate the accuracy of integrated positron emission tomography and computed tomography (PET/CT) using 18-F-fluorodeoxyglucose (FDG), compared with PET alone, in the diagnosis of suspected endometrial cancer recurrence. Methods: Thirty women who had undergone primary surgery for histopathologically proven endometrial cancer with suspected recurrence because of clinical, cytological, biochemical, and/or radiological findings were enrolled in this study. PET and integrated PET/CT images were evaluated by two different experienced radiologists by consensus for each modality. A final diagnosis of recurrence was confirmed by histopathology, other imaging and clinical follow-up for longer than 1 year. The statistical significance of differences between PET and PET/CT was determined by the McNemar test. Results: Patient-based analysis showed that the sensitivity, specificity, and accuracy of PET/CT were 93% (14/15), 93% (14/15), and 93% (28/30), respectively, whereas for PET, the corresponding data were 80% (12/15), 80% (12/15), and 80% (24/30), respectively (P = 0.479, 0.479, and 0.134, respectively). CT from PET/CT resolved the false-positive PET results because of hyper-metabolic activity of benign inflammatory lesions and physiological variants and moreover detected lung metastasis and para-aortic lymph node metastasis that PET missed. However, tiny para-aortic lymph node metastasis could not be detected even with PET/CT. Conclusions: Integrated FDG-PET/CT is a useful complementary modality for providing good anatomic and functional localization of sites of recurrence during follow-up of patients with endometrial cancer.

KW - F-FDG

KW - Endometrial cancer

KW - PET/CT

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=40149092662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40149092662&partnerID=8YFLogxK

U2 - 10.1007/s12149-007-0087-y

DO - 10.1007/s12149-007-0087-y

M3 - Article

C2 - 18311534

AN - SCOPUS:40149092662

VL - 22

SP - 103

EP - 109

JO - Annals of Nuclear Medicine

JF - Annals of Nuclear Medicine

SN - 0914-7187

IS - 2

ER -